Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSPC PHARMA

7.350
-0.340-4.42%
Volume:144.26M
Turnover:1.07B
Market Cap:84.69B
PE:18.29
High:7.710
Open:7.640
Low:7.340
Close:7.690
52wk High:11.454
52wk Low:4.152
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.69
T/O Rate:1.25%
Dividend:0.25
Dividend Rate:3.34%
EPS(LYR):0.402
ROE:10.83%
ROA:5.65%
PB:2.34
PE(LYR):18.29
PS:2.99

Loading ...

HK Stock Connect Shareholding Changes | Oct 28

Stock News
·
Oct 28

CSPC Pharmaceutical Group (1093.HK) Subsidiary CSPC Innovation (300765.SZ) Releases 2025 Third Quarter Results

Bulletin Express
·
Oct 27

CSPC PHARMA (01093): CSPC Innovation Pharmaceutical (300765.SZ) Reports Net Loss of RMB24.05 Million in First Three Quarters

Stock News
·
Oct 27

CSPC Pharmaceutical Group Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 27

Short Selling Statistics of Hong Kong Stocks | October 27

Stock News
·
Oct 27

Capital Flow Statistics of Hong Kong Stock Connect (T+2) | October 27

Stock News
·
Oct 27

BRIEF-CSPC Pharmaceutical Says SYH2061 Injection Obtains Clinical Trial Approval In China

Reuters
·
Oct 24

CSPC Pharma Gets China Nod for IgA Nephropathy Drug Trial

MT Newswires Live
·
Oct 24

Active Trading on Hong Kong Stock Connect | October 24

Stock News
·
Oct 24

CSPC Pharmaceutical Group (1093.HK) Receives Clinical Trial Approval for SYH2061 Injection

Bulletin Express
·
Oct 24

CSPC PHARMA (01093): SYH2061 Injection (Dual-Chain Small Interfering RNA Drug) Approved for Clinical Trials in China

Stock News
·
Oct 24

CSPC Pharmaceutical - Syh2061 Injection Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Oct 24

Hunan Jingfeng's Restructuring Begins: The Multiple Risks and Challenges Behind CSPC Pharma's Takeover

Deep News
·
Oct 24

CSPC Pharmaceutical Group Stock Slips 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 23

Short Selling Statistics of Hong Kong Stocks | October 23

Stock News
·
Oct 23

CSPC Pharmaceutical Group Stock Slides 1.1% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 21

How Breakthrough Therapy Status for JSKN003 at CSPC Pharmaceutical Group (SEHK:1093) Has Changed Its Investment Story

Simply Wall St.
·
Oct 21

BRIEF-CSPC Pharmaceutical Says JSKN003 Granted Breakthrough Therapy Designation In China

Reuters
·
Oct 20

CSPC PHARMA (01093): JSKN 003 Receives Breakthrough Therapy Designation in China for Treatment of HER2-positive Advanced Colorectal Cancer

Stock News
·
Oct 20

CSPC (1093) Gains Second Breakthrough Therapy Designation for JSKN003 in Advanced Colorectal Cancer

Bulletin Express
·
Oct 20